- BioLife Solutions produces HypoThermosol®, CryoStor®, and BloodStor®.
- Studies have shown these proprietary biopreservation media products to significantly reduce both apoptosis and necrosis, the two mechanisms of cell death, in comparison to traditional preservation media.
- Biologics preserved with these media have demonstrated greatly extended shelf life and increased post-preservation cell yield, viability, and functional return.
BioLife Solutions products and services are highly valued in five key market segments; regenerative medicine, cell and tissue banking, cord blood banking, drug discovery, and organ preservation. They estimate the worldwide demand for biopreservation media products to be at least $100 million, and growing at 15-20% per year.
In early 2009, BioLife Solutions completed construction of a state of the art GMP clean room manufacturing suite at their headquarters in Bothell, WA. The facility meets ISO 14644 for Clean Rooms and ISO 13485:2003 for Quality Management Systems. BioLife Solutions has been publicly traded (OTCBB: BLFS) since 2004.
BioLife Solutions also performs contract R & D and consulting services to optimize customer specific biopreservation protocols.